
Kairos Pharma fell 90.9% from $5.00 to $0.46, behind the S&P 500's +8.0%. Its worst day was Oct 6 (−25.8%), and its low came Nov 17 at $0.40.
Nov 19, 2025 – Nov 19, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Kairos Pharma closed at its highest level of the year, 35.9% above where the year started.
+16.9% · S&P 500 0.0%
EPS of $-3.43 missed the $-1.47 estimate on $0.00 revenue.
+3.5% · S&P 500 +0.8%
Story events cover the past 12 months · Times ET
EPS of $-3.92 missed the $-3.43 estimate on $0.00 revenue.
+6.1% · S&P 500 +0.8%
EPS of $-2.94 beat the $-4.41 estimate on $0.00 revenue.
−2.4% · S&P 500 +0.3%
Kairos Pharma shares fell 20.0%, while the S&P 500 fell 0.3%.
−20.0% · S&P 500 −0.3%
Kairos Pharma shares fell 25.8%, while the S&P 500 rose 0.5%.
−25.8%, the year's worst day, on 10M shares, the year's heaviest volume · S&P 500 +0.5%
EPS of $-0.59 beat the $-0.63 estimate on $0.00 revenue.
−10.3% · S&P 500 −1.9%
Where it ended: a close of $0.46 on Nov 19, 2026.
Nothing in the past 12 months.
All KAPA dividend historyChart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for KAPA and SPY from Benzinga historical bars. Not investment advice.